Genome Editing in Engineered T Cells for Cancer Immunotherapy
Advanced gene transfer technologies and profound immunological insights have enabled substantial increases in the efficacy of anticancer adoptive cellular therapy (ACT). In recent years, the U.S. Food and Drug Administration and European Medicines Agency have approved six engineered T cell therapeut...
Saved in:
| Published in: | Human gene therapy Vol. 34; no. 17-18; p. 853 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.09.2023
|
| Subjects: | |
| ISSN: | 1557-7422, 1557-7422 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Advanced gene transfer technologies and profound immunological insights have enabled substantial increases in the efficacy of anticancer adoptive cellular therapy (ACT). In recent years, the U.S. Food and Drug Administration and European Medicines Agency have approved six engineered T cell therapeutic products, all chimeric antigen receptor-engineered T cells directed against B cell malignancies. Despite encouraging clinical results, engineered T cell therapy is still constrained by challenges, which could be addressed by genome editing. As RNA-guided Clustered Regularly Interspaced Short Palindromic Repeats technology passes its 10-year anniversary, we review emerging applications of genome editing approaches designed to (1) overcome resistance to therapy, including cancer immune evasion mechanisms; (2) avoid unwanted immune reactions related to allogeneic T cell products; (3) increase fitness, expansion capacity, persistence, and potency of engineered T cells, while preserving their safety profile; and (4) improve the ability of therapeutic cells to resist immunosuppressive signals active in the tumor microenvironment. Overall, these innovative approaches should widen the safe and effective use of ACT to larger number of patients affected by cancer. |
|---|---|
| AbstractList | Advanced gene transfer technologies and profound immunological insights have enabled substantial increases in the efficacy of anticancer adoptive cellular therapy (ACT). In recent years, the U.S. Food and Drug Administration and European Medicines Agency have approved six engineered T cell therapeutic products, all chimeric antigen receptor-engineered T cells directed against B cell malignancies. Despite encouraging clinical results, engineered T cell therapy is still constrained by challenges, which could be addressed by genome editing. As RNA-guided Clustered Regularly Interspaced Short Palindromic Repeats technology passes its 10-year anniversary, we review emerging applications of genome editing approaches designed to (1) overcome resistance to therapy, including cancer immune evasion mechanisms; (2) avoid unwanted immune reactions related to allogeneic T cell products; (3) increase fitness, expansion capacity, persistence, and potency of engineered T cells, while preserving their safety profile; and (4) improve the ability of therapeutic cells to resist immunosuppressive signals active in the tumor microenvironment. Overall, these innovative approaches should widen the safe and effective use of ACT to larger number of patients affected by cancer. Advanced gene transfer technologies and profound immunological insights have enabled substantial increases in the efficacy of anticancer adoptive cellular therapy (ACT). In recent years, the U.S. Food and Drug Administration and European Medicines Agency have approved six engineered T cell therapeutic products, all chimeric antigen receptor-engineered T cells directed against B cell malignancies. Despite encouraging clinical results, engineered T cell therapy is still constrained by challenges, which could be addressed by genome editing. As RNA-guided Clustered Regularly Interspaced Short Palindromic Repeats technology passes its 10-year anniversary, we review emerging applications of genome editing approaches designed to (1) overcome resistance to therapy, including cancer immune evasion mechanisms; (2) avoid unwanted immune reactions related to allogeneic T cell products; (3) increase fitness, expansion capacity, persistence, and potency of engineered T cells, while preserving their safety profile; and (4) improve the ability of therapeutic cells to resist immunosuppressive signals active in the tumor microenvironment. Overall, these innovative approaches should widen the safe and effective use of ACT to larger number of patients affected by cancer.Advanced gene transfer technologies and profound immunological insights have enabled substantial increases in the efficacy of anticancer adoptive cellular therapy (ACT). In recent years, the U.S. Food and Drug Administration and European Medicines Agency have approved six engineered T cell therapeutic products, all chimeric antigen receptor-engineered T cells directed against B cell malignancies. Despite encouraging clinical results, engineered T cell therapy is still constrained by challenges, which could be addressed by genome editing. As RNA-guided Clustered Regularly Interspaced Short Palindromic Repeats technology passes its 10-year anniversary, we review emerging applications of genome editing approaches designed to (1) overcome resistance to therapy, including cancer immune evasion mechanisms; (2) avoid unwanted immune reactions related to allogeneic T cell products; (3) increase fitness, expansion capacity, persistence, and potency of engineered T cells, while preserving their safety profile; and (4) improve the ability of therapeutic cells to resist immunosuppressive signals active in the tumor microenvironment. Overall, these innovative approaches should widen the safe and effective use of ACT to larger number of patients affected by cancer. |
| Author | Guedan, Sonia Bonini, Chiara Hudecek, Michael Chapuis, Aude G Magnani, Chiara Qasim, Waseem |
| Author_xml | – sequence: 1 givenname: Chiara orcidid: 0000-0002-0772-1674 surname: Bonini fullname: Bonini, Chiara organization: Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele Scientific Institute, Milan, Italy – sequence: 2 givenname: Aude G surname: Chapuis fullname: Chapuis, Aude G organization: Department of Oncology, University of Washington, Seattle, Washington, USA – sequence: 3 givenname: Michael surname: Hudecek fullname: Hudecek, Michael organization: Lehrstuhl für Zelluläre Immuntherapie, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany – sequence: 4 givenname: Sonia surname: Guedan fullname: Guedan, Sonia organization: Department of Hematology and Oncology, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain – sequence: 5 givenname: Chiara surname: Magnani fullname: Magnani, Chiara organization: Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Comprehensive Cancer Center Zurich (CCCZ), Zurich, Switzerland – sequence: 6 givenname: Waseem surname: Qasim fullname: Qasim, Waseem organization: UCL Great Ormond Street Institute of Child Health, London, United Kingdom |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37694593$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNjzFPwzAUhC1URGlhY0YeWVLsZyeOBwYUlVKpEkuZI9t5aYNqp9jJ0H9PJYrEdDd8Ot03I5PQByTkgbMFZ6V-3o9-AQzEgkN5RW55nqtMSYDJvz4ls5S-GOMiL9QNmQpVaJlrcUteVhh6j3TZdEMXdrQLdBl2XUCM2NAtrfBwSLTtI61McBjp2vsx9MMeozme7sh1aw4J7y85J59vy231nm0-VuvqdZM5yfWQCbRFKV1ulWvBARQcS2nBOt02ruFgciYNK9BarXjr0CiOwgCTshGuBAtz8vS7e4z994hpqH2X3PmaCdiPqYayOCspLdQZfbygo_XY1MfYeRNP9Z8y_ACPX1lQ |
| CitedBy_id | crossref_primary_10_1158_2326_6066_CIR_24_0251 crossref_primary_10_1182_bloodadvances_2025016366 crossref_primary_10_1038_s41408_025_01260_6 crossref_primary_10_1038_s41467_024_47799_z crossref_primary_10_1055_a_2491_3652 crossref_primary_10_1016_j_copbio_2024_103127 crossref_primary_10_1016_j_compbiomed_2024_109137 crossref_primary_10_3389_fimmu_2025_1647433 crossref_primary_10_1038_s41571_025_01072_4 crossref_primary_10_3389_fimmu_2025_1615212 crossref_primary_10_3389_fimmu_2024_1385571 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1089/hum.2023.128 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1557-7422 |
| ExternalDocumentID | 37694593 |
| Genre | Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: Department of Health – fundername: Wellcome Trust – fundername: Medical Research Council |
| GroupedDBID | --- .55 .GJ 0R~ 29I 34G 39C 4.4 53G 5GY 5RE ABBKN ABJNI ACGFO ACGFS ACIWK ACPRK ADBBV AENEX AFRAH ALMA_UNASSIGNED_HOLDINGS BNQNF CAG CGR COF CS3 CUY CVF DU5 EBS ECM EIF EJD F5P IAO IER IGS IH2 IHR ITC L7B MV1 NPM NQHIM O9- P2P R.V RIG RML RMSOB UE5 X7M Y6R ZGI ZXP 7X8 SCNPE |
| ID | FETCH-LOGICAL-c419t-3eb684c5b7cf2c2261e84b2bc9fdcd12a504a06ebb971fcea71e3a2044d3c82b2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 11 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001070254500009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1557-7422 |
| IngestDate | Thu Sep 04 19:10:24 EDT 2025 Mon Jul 21 06:04:34 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 17-18 |
| Keywords | CRISPR CAR TCR |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c419t-3eb684c5b7cf2c2261e84b2bc9fdcd12a504a06ebb971fcea71e3a2044d3c82b2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-0772-1674 |
| OpenAccessLink | https://pmc.ncbi.nlm.nih.gov/articles/PMC10623081/pdf/hum.2023.128.pdf |
| PMID | 37694593 |
| PQID | 2863767937 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2863767937 pubmed_primary_37694593 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-09-00 20230901 |
| PublicationDateYYYYMMDD | 2023-09-01 |
| PublicationDate_xml | – month: 09 year: 2023 text: 2023-09-00 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Human gene therapy |
| PublicationTitleAlternate | Hum Gene Ther |
| PublicationYear | 2023 |
| SSID | ssj0013567 |
| Score | 2.4819305 |
| SecondaryResourceType | review_article |
| Snippet | Advanced gene transfer technologies and profound immunological insights have enabled substantial increases in the efficacy of anticancer adoptive cellular... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 853 |
| SubjectTerms | Anniversaries and Special Events B-Lymphocytes Gene Editing Humans Immunotherapy Neoplasms - genetics Neoplasms - therapy T-Lymphocytes United States |
| Title | Genome Editing in Engineered T Cells for Cancer Immunotherapy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37694593 https://www.proquest.com/docview/2863767937 |
| Volume | 34 |
| WOSCitedRecordID | wos001070254500009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFA7qVHzxMm_zRgRfo22StsmTyNhQcGMPU_Y2cjnFwWznLsL-vUnboS-C4EsJlEI5-ZJzkvOd8yF0w0xsGZcpkUmoiPPXARFaGeLAYyKtYxCFJMvrc9LtisFA9qoLt1lFq1zticVGbXPj78jvqIh94xHnTe8nH8SrRvnsaiWhsY5qzIUyntKVDH5kEaJCQda5zIS4IyCtiO-BkHdvC1-GTtltSMXvwWXhZNp7__29fbRbhZf4ocTDAVqDrI62SsHJZR1td6pU-iHyInL5O-CWHXnmMx5leNWbECzu4yaMxzPsQlrc9MCY4idfSVLVay2P0Eu71W8-kkpLgRgeyjlhoGPBnfkTk1LjYq4QBNdUG5laY0OqooCrIAat3aSlBlQSAlM04NwyI6imx2gjyzM4RZinMjUBAx5a7cZMpTEYq0CCjCNNeQNdr0w0dFj1CQiVQb6YDb-N1EAnpZ2Hk7KpxtC9kDyS7OwPX5-jHT93JdXrAtVSt1LhEm2az_loNr0qQOCe3V7nC6dmvCA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genome+Editing+in+Engineered+T+Cells+for+Cancer+Immunotherapy&rft.jtitle=Human+gene+therapy&rft.au=Bonini%2C+Chiara&rft.au=Chapuis%2C+Aude+G&rft.au=Hudecek%2C+Michael&rft.au=Guedan%2C+Sonia&rft.date=2023-09-01&rft.eissn=1557-7422&rft.volume=34&rft.issue=17-18&rft.spage=853&rft_id=info:doi/10.1089%2Fhum.2023.128&rft_id=info%3Apmid%2F37694593&rft_id=info%3Apmid%2F37694593&rft.externalDocID=37694593 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1557-7422&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1557-7422&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1557-7422&client=summon |